MARKET

ELDN

ELDN

Eledon Pharmaceuticals Inc
NASDAQ
3.200
-0.120
-3.61%
After Hours: 3.210 +0.01 +0.31% 19:30 08/28 EDT
OPEN
3.290
PREV CLOSE
3.320
HIGH
3.320
LOW
3.170
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
4.600
52 WEEK LOW
1.350
MARKET CAP
260.04M
P/E (TTM)
-3.3309
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ELDN last week (0817-0821)?
Weekly Report · 5d ago
Weekly Report: what happened at ELDN last week (0810-0814)?
Weekly Report · 08/17 10:24
Eledon Pharmaceuticals reports Q2 EPS (27c), consensus (15c)
TipRanks · 08/16 14:03
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/14 15:00
Eledon Therapeutics: Buy Rating Reaffirmed on Strong Cash Runway and Tegoprubart Data; Price Target Unchanged at $8
TipRanks · 08/14 10:15
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Benzinga · 08/13 20:30
Eledon Pharmaceuticals GAAP EPS of -$0.27 misses by $0.11
Seeking Alpha · 08/13 20:30
Press Release: Eledon Pharmaceuticals Reports -2-
Dow Jones · 08/13 20:05
More
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Webull offers Eledon Pharmaceuticals Inc stock information, including NASDAQ: ELDN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ELDN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ELDN stock methods without spending real money on the virtual paper trading platform.